Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Avanafil (TA1790) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
25 mg | 在庫あり | ¥ 11,000 | |||
50 mg | 在庫あり | ¥ 13,500 | |||
100 mg | 在庫あり | ¥ 21,500 | |||
200 mg | 在庫あり | ¥ 26,000 | |||
500 mg | 在庫あり | ¥ 32,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 11,500 |
説明 | Avanafil (TA1790) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction. |
ターゲット&IC50 | PDE5:1 nM |
In vitro | In the corpus cavernosum of rats with Type 2 Diabetes Mellitus (T2DM), the injection of Avanafil (1 μM) has been demonstrated to enhance erectile function. |
別名 | TA1790 |
分子量 | 483.95 |
分子式 | C23H26ClN7O3 |
CAS No. | 330784-47-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 90 mg/mL (186 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Avanafil 330784-47-9 Metabolism PDE Phosphodiesterase (PDE) bone density TA-1790 Endogenous Metabolite Inhibitor osteoporosis dexamethasone NOS Nitric oxide synthases corpus cavernosum erectile dysfunction inhibit NO Synthase TA 1790 TA1790 inhibitor